Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cilnidipine + metoprolol succinate (Med Manor Organics)
- Development stage
- Unknown
- Lead developer
- Med Manor Organics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Cilory-M is an oral fixed-dose combination therapy developed by Med Manor Organics for the treatment of hypertension. It contains two active pharmaceutical ingredients: cilnidipine, a dual L-type and N-type calcium channel blocker, and metoprolol succinate, a cardioselective beta-1 adrenergic receptor blocker. Cilnidipine acts on L-type calcium channels in vascular smooth muscle to induce vasodilation and on N-type calcium channels in sympathetic nerve terminals to suppress norepinephrine release, thereby preventing reflex tachycardia. Metoprolol succinate selectively blocks beta-1 adrenergic receptors in the heart, reducing heart rate, myocardial contractility, and cardiac output. Together, these complementary mechanisms synergistically lower blood pressure and reduce the workload on the heart, providing effective cardiovascular protection.
- Brand names
- Cilory-MCilory-M 25Cilory-M25Cilory-M-25Cilory-M 50Cilory-M50Cilory-M-50
- Other names
- cilnidipine + metoprololcilnidipine + metoprolol succinate
02
Targets
LTCC (Voltage-gated calcium channel (L-type))CACNA1B (Voltage-dependent N-type calcium channel subunit alpha-1B)ADRB1 (β1)ADRB2 (β2)CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)
Beyond the preview
Go deeper on cilnidipine + metoprolol succinate (Med Manor Organics).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cilnidipine + metoprolol succinate (Med Manor Organics).